Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:06:21.234Z.
Calculation as of: 2026-10-06T17:06:21.234Z.
Quote observation: 2026-10-06T16:54:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 416ecde9e74d9373f9380d00a8c5b89f0781d1fb8694113a8adf0a2929208a5a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$16.08M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.31M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$16.50M
EV/EBIT Ratio
N/A
TTM Avg
188.96x
3Y Avg
135.60x
5Y Avg
135.60x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | $15.25M | N/A | N/A | N/A | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.98M | N/A | N/A | N/A | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.59M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $15.85M | N/A | 33.55x | 33.49x | 33.49x |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $16.08M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.31M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.50M | N/A | 188.96x | 135.60x | 135.60x |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.10M | N/A | N/A | N/A | N/A |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute